Northwest Biotherapeutics' Near Term Plans for Marketing Authorization Application Submission
Northwest Biotherapeutics is providing an update on its progress towards submitting a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for its DCVax-L treatment for glioblastoma. The majority of the MAA has been completed, with only one key section remaining. The company plans to submit applications to multiple regulators and is taking additional time to ensure the MAA package is strong. The remaining section is expected to be delivered to the publisher within two weeks, with the MAA submission anticipated to take place between mid and late November.